The data is big,please wait a moment......
| EWAS ID | GO ID | Class | Disease/Phenotype [sample size n] |
Sample groups (case/control, trait, cell type etc.) |
Categories | GO Term Name | GO Term Gene Number | Gene Number Annotated In The GO Term | Pvalue | |
| Group1 [sample size n] |
Group2 [sample size n] |
|||||||||
| EWAS1296 | GO:0050670 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | regulation of lymphocyte proliferation | 106 | 86 | 0.000986 |
| EWAS1296 | GO:0050671 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | positive regulation of lymphocyte proliferation | 75 | 63 | 0.000586 |
| EWAS1296 | GO:0050673 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | epithelial cell proliferation | 167 | 132 | 0.000685 |
| EWAS1296 | GO:0050714 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | positive regulation of protein secretion | 48 | 42 | 0.000521 |
| EWAS1296 | GO:0050727 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | regulation of inflammatory response | 105 | 86 | 0.000534 |
| EWAS1296 | GO:0050729 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | positive regulation of inflammatory response | 47 | 43 | 0.000030 |
| EWAS1296 | GO:0050730 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | regulation of peptidyl-tyrosine phosphorylation | 84 | 72 | 0.000067 |
| EWAS1296 | GO:0050731 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | positive regulation of peptidyl-tyrosine phosphorylation | 66 | 57 | 0.000192 |
| EWAS1296 | GO:0050764 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | regulation of phagocytosis | 22 | 21 | 0.000223 |
| EWAS1296 | GO:0050766 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | positive regulation of phagocytosis | 17 | 17 | 0.000000 |